Building an OXPHOS-Deficient Cell Line
The Three Routes
| Route | What is removed | Time | Reversibility |
|---|---|---|---|
| ρ0 (mtDNA depletion) | All mtDNA-encoded subunits | 4–12 weeks | Effectively irreversible |
| Nuclear gene knockout (e.g. NDUFS1, SDHB) | One complex | 6–16 weeks | Clonal; irreversible |
| Cybrid | mtDNA variant, common nuclear background | 8–16 weeks | Irreversible |
Important distinction. ρ0 cells remove complex I, III, IV and ATP synthase subunits simultaneously while leaving complex II intact. A nuclear knockout removes one complex. The two are not interchangeable models, and a phenotype in ρ0 cells cannot be attributed to a specific complex.
Part 1 — Generating ρ0 Cells
| Step | Detail | Note |
|---|---|---|
| Agent | Low-dose ethidium bromide, or ddC | Ethidium bromide intercalates mtDNA preferentially at low dose |
| Supplementation | Uridine (50 µg/mL) and pyruvate (1 mM) | Required for growth once mtDNA is lost |
| Duration | 4–12 weeks, with periodic testing | Longer for some lines |
| Verification | mtDNA qPCR; OCR; complex IV activity | Multiple independent checks |
| Maintenance | Continued uridine and pyruvate | Removal causes death |
| Documentation | Passage and generation time | Adaptation accumulates |
Caveat on the auxotrophy. Uridine is required because dihydroorotate dehydrogenase, a step in pyrimidine synthesis, is mitochondrial and depends on the electron transport chain. Pyruvate provides a cytosolic NAD⁺ regeneration route. Both must be present from the point of mtDNA loss, and their presence is part of the model's definition, not a technical detail.
Part 2 — What Adapts
| Adaptation | Consequence |
|---|---|
| Increased glycolytic capacity | Lactate production rises; glucose dependence increases |
| Altered mitochondrial mass | Content may rise or fall depending on the line |
| Changes in aspartate supply | Proliferation may require exogenous aspartate or pyruvate |
| Altered signalling | AMPK activation, HIF stabilisation in some lines |
| Selection | Clones with the fastest growth dominate |
Important distinction. A ρ0 line is a long-term adaptation, not an acute knockout. Many of its phenotypes reflect what the cell did over weeks to survive, and comparisons with the parental line confound the loss of mtDNA with that adaptation. An inducible system, where available, is the cleaner design for acute questions.
Part 3 — Nuclear Knockouts
| Target | Effect | Caveat |
|---|---|---|
| NDUFS1, NDUFA9 | Complex I loss | Some lines cannot tolerate it |
| SDHB, SDHC | Complex II loss | Succinate accumulates; epigenetic effects |
| UQCRB | Complex III loss | Lethal in many lines |
| COX10, SCO2 | Complex IV assembly | Partial loss often obtainable |
| ATP5A1 | ATP synthase | Viable in some lines; gradient hyperpolarises |
Readout note. A nuclear knockout must be verified at three levels: genotype, protein (subunit immunoblot), and function (substrate-specific respiration). A genotype-only verification can miss a hypomorphic allele, and in the ETC a partial loss often produces a different phenotype from a complete one.
Part 4 — Verification Package
| Check | Method | Passing criterion |
|---|---|---|
| mtDNA content | qPCR, mitochondrial versus nuclear amplicon | Undetectable or strongly reduced for ρ0 |
| Complex activity | Blue-native in-gel activity; isolated enzyme assay | Absent for the targeted complex |
| Substrate-specific respiration | Permeabilised cells | Absent response to the relevant substrate |
| Complex II control | Succinate-linked respiration | Preserved in ρ0 |
| Growth requirement | Uridine/pyruvate dependence | Required for ρ0 |
| Content | Citrate synthase activity or mtDNA | Reported alongside function |
The sixth row matters for interpretation: citrate synthase activity is a standard content marker, and a line with reduced content but normal per-mitochondrion respiration is a different model from one with a specific complex defect.
Part 5 — Common Failures
- • ρ0 described as "OXPHOS-deficient" without noting the auxotrophy and adaptation.
- • Single verification method used, usually mtDNA qPCR alone.
- • Uridine or pyruvate omitted, so the line cannot grow and the experiment is abandoned.
- • Complex II control omitted, so a global assay problem looks like a specific defect.
- • Nuclear knockout verified by genotype only.
- • Parental comparison at a different passage, confounding adaptation with genotype.
- • Content not measured, so a specific defect is indistinguishable from fewer mitochondria.
- • Cybrid nuclear background not matched, confounding the mtDNA variant with nuclear variation.
Part 6 — Where This Article Connects
This is the model-building article of the mitochondrial cluster. The respiratory chain article covers what the complexes are and which readouts distinguish capacity, coupling and content; the Seahorse article covers the functional measurement; and the inhibitor article covers acute alternatives to genetic models.
If you need OXPHOS-deficient models with a three-level verification package, we can scope the build with you.
Contact EDITGENE to request a project consultation or quote.
Scientific scope and validation note
ρ0 generation efficiency, adaptation and viability vary widely between lines, and nuclear knockouts of ETC subunits are not tolerated in all backgrounds.
Loss of mtDNA is not equivalent to loss of a specific complex, and a verified defect does not establish that respiratory capacity limits a phenotype.
Scientific interpretation and experimental design
- • Three routes, three models. Choose by question.
- • ρ0 is auxotrophic. Uridine and pyruvate are part of the model.
- • Adaptation is the confound. Match passage, or use inducible systems.
- • Verify at three levels. Genotype, protein, function.
- • Keep complex II as the control.
- • Measure content. Fewer mitochondria is not a specific defect.
Selected references for further reading
- • King MP, Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science. 1989;246:500–503.
- • Chandel NS, Schumacker PT. Cells depleted of mitochondrial DNA (ρ0) yield insight into physiological mechanisms. FEBS Letters. 1999;454:173–176.
- • Vercellino I, Sazanov LA. The assembly, regulation and function of the mitochondrial respiratory chain. Nature Reviews Molecular Cell Biology. 2022;23:141–161.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »